1. Heit JA: The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28(3): 370-2
  2. Cohen AT et al.: Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98(4): 756-64
  3. Konstantinides SV et al.: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(43): 3033-69, 3069a-3069k
  4. Kearon C et al.: Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149(2): 315-52
  5. Boutitie F et al.: Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011; 342: d3036
  6. Prandoni P et al.: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125(1): 1-7
  7. Akl EA et al.: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (6): CD006650
  8. Prandoni P et al.: The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92(2): 199-205
  9. Kyrle PA et al.: The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost 2016; 14(12): 2402-9
  10. Agnelli G et al.: Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368(8): 699-708
  11. Weitz JI et al.: Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376(13): 1211-22
  12. Rodger MA et al.: Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179(5): 417-26
  13. Eichinger S et al.: Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010; 121(14): 1630-6
  14. Tosetto A et al.: Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10(6): 1019-25
  15. science-research/software/clinical-software/recurrent-vte/, letzter Aufruf 12. 12. 2017